Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
Status:
Not yet recruiting
Trial end date:
2024-12-15
Target enrollment:
Participant gender:
Summary
Two strategies have both proven to be effective in reducing bleeding complications while
preserving efficacy compared with maintaining long-term DAPT with aspirin and a potent P2Y12
inhibitor: a) DAPT de-escalation (i.e., switching from prasugrel or ticagrelor to clopidogrel
while maintaining aspirin) and b) potent P2Y12 inhibitor monotherapy (i.e., maintaining
prasugrel or ticagrelor and dropping aspirin). These strategies have been tested in a number
of trials and have led to changes in practice guidelines to consider either one of these
strategies as bleeding reduction approaches among ACS patients undergoing PCI. However,
comparative assessments between DAPT de-escalation and potent P2Y12 inhibitor monotherapy are
lacking.